The sensitivity of different methods for detecting abnormalities in auditory nerve function

Lu, Tianhao; Li, Qiang; Zhang, Chen; Chen, Min; Wang, Zhengming; Li, Shufeng

doi:10.1186/s12938-020-0750-2

Cited by 1 publication

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This retrospective study was approved by Stony Brook University Institutional Research Board with exemption of informed consent. A subset of these data has been used to study different aspects of COVID-19 disease (17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28). Figure 1 shows patients who presented to the emergency department (ED) and were hospitalized with COVID-19 from February 7, 2020, to June 30, 2020.…”

Section: Study Population and Data Collectionmentioning

confidence: 99%

Longitudinal Clinical Profiles of Hospital vs. Community-Acquired Acute Kidney Injury in COVID-19

Babatsikos

Fisher

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Acute kidney injury (AKI) is associated with high mortality in coronavirus disease 2019 (COVID-19). However, it is unclear whether patients with COVID-19 with hospital-acquired AKI (HA-AKI) and community-acquired AKI (CA-AKI) differ in disease course and outcomes. This study investigated the clinical profiles of HA-AKI, CA-AKI, and no AKI in patients with COVID-19 at a large tertiary care hospital in the New York City area. The incidence of HA-AKI was 23.26%, and CA-AKI was 22.28%. Patients who developed HA-AKI were older and had more comorbidities compared to those with CA-AKI and those with no AKI (p < 0.05). A higher prevalence of coronary artery disease, heart failure, and chronic kidney disease was observed in those with HA-AKI compared to those with CA-AKI (p < 0.05). Patients with CA-AKI received more invasive and non-invasive mechanical ventilation, anticoagulants, and steroids compared to those with HA-AKI (p < 0.05), but patients with HA-AKI had significantly higher mortality compared to those with CA-AKI after adjusting for demographics and clinical comorbidities (adjusted odds ratio = 1.61, 95% confidence interval = 1.1–2.35, p < 0.014). In addition, those with HA-AKI had higher markers of inflammation and more liver injury (p < 0.05) compared to those with CA-AKI. These results suggest that HA-AKI is likely part of systemic multiorgan damage and that kidney injury contributes to worse outcomes. These findings provide insights that could lead to better management of COVID-19 patients in time-sensitive and potentially resource-constrained environments.

show abstract